INT J TUBERC LUNG DIS 15(7): 4 HIV is also known to increase the rates of recurrent TB disease after successful completion of treatment for a fi rst episode. [4][5][6] As a result of the impact of HIV, countries with high HIV prevalence have had a two-to fi ve-fold increase in annual TB case notifi cation rates over the last decade. 4,7 This increase in TB burden has adversely affected TB programmes and has strained available human and fi nancial resources at programme level. 4,8 Observational cohort studies in a wide range of settings have demonstrated that antiretroviral treatment (ART), through immune reconstitution, is associated with a 54% to 92% reduction in TB incidence at the individual patient level and a halving of the risk of TB recurrence. 7,9-13 It logically follows that if a large proportion of HIV-positive individuals in high HIV prevalence settings are offered ART, the reduction in TB incidence at the individual patient level should also have a benefi cial impact on TB incidence and case notifi cation at the population level. However, empirical data on the impact of ART on TB case notifi cation at the community level are lacking. 7 Thyolo District in rural southern Malawi had a global and adult HIV prevalence of respectively 10% and 21% in 2007. 14 The district has been progressively scaling up HIV/AIDS (acquired immune-defi ciency syndrome) care and ART since 2003. The district achieved and sustained universal ART access from 2007 onwards (sustained access for at least 80% of those in need). 15,16 We hypothesised that such a large scale-up and coverage of ART at the population level might have been associated with a decrease in district TB case notifi cations. We thus report on trends in new and recurrent TB case notifi cations at the
S U M M A R Y